July 12th 2022

Published in JAMA Oncology: Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Published in JAMA Oncology: Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

The CARE partner Centre Hospitalier Universitaire Vaudois (CHUV) in collaboration with Lausanne University Hospital published a paper reporting on the durability of neutralizing antibody responses elicited by messenger RNA vaccines BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) against the SARS-CoV-2 variants of concern (VOCs) in immunocompromised patients and healthy controls. The study showed a loss of neutralizing antibody response against the circulating VOCs at 6 months after vaccination, the loss being demonstrably greater for immunocompromised patients.

To learn more, click here: Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients